Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable

Simply Wall St.05-31

Key Insights Sutro Biopharma to hold its Annual General Meeting on 6th of June Total pay for CEO Bill Newell includes US$686.7k salary Total compensation is 33% below industry average Sutro ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2439964322?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","is_english":true,"pubTime":"2024-05-31 18:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2439964322","market":"us","top_or_hot":-1,"title":"Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable","media":"Simply Wall St.","content":"<div>\n<p>Key Insights\n\n Sutro Biopharma to hold its Annual General Meeting on 6th of June \n Total pay for CEO Bill Newell includes US$686.7k salary \n Total compensation is 33% below industry average \n Sutro ...</p>\n\n<a href=\"https://finance.yahoo.com/news/shareholders-likely-sutro-biopharma-inc-101623813.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-31 18:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/shareholders-likely-sutro-biopharma-inc-101623813.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights\n\n Sutro Biopharma to hold its Annual General Meeting on 6th of June \n Total pay for CEO Bill Newell includes US$686.7k salary \n Total compensation is 33% below industry average \n Sutro ...</p>\n\n<a href=\"https://finance.yahoo.com/news/shareholders-likely-sutro-biopharma-inc-101623813.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QQQ","symbol_name":"纳指100ETF","start_time":0,"source_url":"https://finance.yahoo.com/news/shareholders-likely-sutro-biopharma-inc-101623813.html","article_id":"2439964322","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2439964322","pubTimestamp":1717150583,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Sutro Biopharma to hold its Annual General Meeting on 6th of June. Total pay for CEO Bill Newell includes US$686.7k salary. Sutro Biopharma's three-year loss to shareholders was 77% while its EPS was down 4.2% over the past three years. The performance at Sutro Biopharma, Inc.  has been rather lacklustre of late and shareholders may be wondering what CEO Bill Newell is planning to do about this. They will get a chance to exercise their voting power to influence the future direction of the company in the next AGM on 6th of June. Setting appropriate executive remuneration to align with the interests of shareholders may also be a way to influence the company performance in the long run. In our opinion, CEO compensation does not look excessive and we discuss why.How Does Total Compensation For Bill Newell Compare With Other Companies In The Industry?The return of -77% over three years would not have pleased Sutro Biopharma, Inc. shareholders. Thi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QQQ":"纳指100ETF","TQQQ":"纳指三倍做多ETF","BK4585":"ETF&股票定投概念","PSQ":"纳指反向ETF","QID":"纳指两倍做空ETF","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","STRO":"Sutro Biopharma Inc","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SQQQ":"纳指三倍做空ETF"},"translate_title":"股东可能会认为Sutro Biopharma，Inc.（纳斯达克股票代码：STRO）首席执行官的薪酬是可以接受的","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STRO":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights\n\n Sutro Biopharma to hold its Annual General Meeting on 6th of June \n Total pay for CEO Bill Newell includes US$686.7k salary \n Total compensation is 33% below industry average \n Sutro Biopharma's three-year loss to shareholders was 77% while its EPS was down 4.2% over the past three years  \n\n The performance at Sutro Biopharma, Inc. (NASDAQ:STRO) has been rather lacklustre of late and shareholders may be wondering what CEO Bill Newell is planning to do about this. They will get a chance to exercise their voting power to influence the future direction of the company in the next AGM on 6th of June. Setting appropriate executive remuneration to align with the interests of shareholders may also be a way to influence the company performance in the long run. In our opinion, CEO compensation does not look excessive and we discuss why. \n View our latest analysis for Sutro Biopharma \n How Does Total Compensation For Bill Newell Compare With Other Companies In The Industry? \n At the time of writing, our data shows that Sutro Biopharma, Inc. has a market capitalization of US$354m, and reported total annual CEO compensation of US$2.1m for the year to December 2023. Notably, that's a decrease of 30% over the year before. While we always look at total compensation first, our analysis shows that the salary component is less, at US$687k. \n On comparing similar companies from the American Biotechs industry with market caps ranging from US$200m to US$800m, we found that the median CEO total compensation was US$3.2m. That is to say, Bill Newell is paid under the industry median. Moreover, Bill Newell also holds US$1.5m worth of Sutro Biopharma stock directly under their own name. \n\n\n\nComponent\n2023\n2022\nProportion (2023)\n\n\nSalary\nUS$687k\nUS$663k\n32%\n\n\nOther\nUS$1.4m\nUS$2.4m\n68%\n\n\nTotal Compensation\nUS$2.1m \nUS$3.0m\n100%\n\n\n\n Speaking on an industry level, nearly 23% of total compensation represents salary, while the remainder of 77% is other remuneration. Sutro Biopharma is paying a higher share of its remuneration through a salary in comparison to the overall industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance. \n\n\n\n  NasdaqGM:STRO CEO Compensation May 31st 2024\n \n\n A Look at Sutro Biopharma, Inc.'s Growth Numbers \n Sutro Biopharma, Inc. has reduced its earnings per share by 4.2% a year over the last three years. In the last year, its revenue is up 107%. \n Investors would be a bit wary of companies that have lower EPS But in contrast the revenue growth is strong, suggesting future potential for EPS growth. In conclusion we can't form a strong opinion about business performance yet; but it's one worth watching. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings.. \nHas Sutro Biopharma, Inc. Been A Good Investment?\n The return of -77% over three years would not have pleased Sutro Biopharma, Inc. shareholders. This suggests it would be unwise for the company to pay the CEO too generously. \n In Summary... \n The fact that shareholders are sitting on a loss is certainly disheartening. The fact that earnings growth has gone backwards could be a factor for the downward trend in the share price. In the upcoming AGM, shareholders should take this opportunity to raise these concerns with the board and revisit their investment thesis with regards to the company. \n While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. We did our research and spotted 3 warning signs for Sutro Biopharma that investors should look into moving forward. \n Switching gears from Sutro Biopharma, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look. \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2439964322"}